Five Years of Successful Inducible Transgene Expression Following Locoregional Adeno-Associated Virus Delivery in Nonhuman Primates with No Detectable Immunity
Restricted accessResearch articleFirst published online July, 2019
Five Years of Successful Inducible Transgene Expression Following Locoregional Adeno-Associated Virus Delivery in Nonhuman Primates with No Detectable Immunity
Anti-transgene immune responses elicited after intramuscular (i.m.) delivery of recombinant adeno-associated virus (rAAV) have been shown to hamper long-term transgene expression in large-animal models of rAAV-mediated gene transfer. To overcome this hurdle, an alternative mode of delivery of rAAV vectors in nonhuman primate muscles has been described: the locoregional (LR) intravenous route of administration. Using this injection mode, persistent inducible transgene expression for at least 1 year under the control of the tetracycline-inducible Tet-On system was previously reported in cynomolgus monkeys, with no immunity against the rtTA transgene product. The present study shows the long-term follow-up of these animals. It is reported that LR delivery of a rAAV2/1 vector allows long-term inducible expression up to at least 5 years post gene transfer, with no any detectable host immune response against the transactivator rtTA, despite its immunogenicity following i.m. gene transfer. This study shows for the first time a long-term regulation of muscle gene expression using a Tet-On-inducible system in a large-animal model. Moreover, these findings further confirm that the rAAV LR delivery route is efficient and immunologically safe, allowing long-term skeletal muscle gene transfer.
Get full access to this article
View all access options for this article.
References
1.
BüningH. Gene therapy enters the pharma market: the short story of a long journey. EMBO Mol Med, 2013; 5:1–3.
2.
BurnettJR, HooperAJ. Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency. Curr Opin Mol Ther, 2009; 11:681–691.
3.
GinnSL, AmayaAK, AlexanderIE, et al.Gene therapy clinical trials worldwide to 2017: an update. J Gene Med, 2018; 20:e3015.
4.
Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy. Med Lett Drugs Ther, 2018; 60:53–55.
5.
ErtlHC, HighKA. The impact of AAV capsid-specific T-cell responses on design and outcome of clinical gene transfer trials with recombinant adeno-associated viral vectors: an evolving controversy. Hum Gene Ther, 2017; 28:328–337.
6.
MannoCS, PierceGF, ArrudaVR, et al.Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med, 2006; 12:342–347.
7.
MingozziF, MeulenbergJJ, HuiDJ, et al.AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood, 2009; 114:2077–2086.
8.
FavreD, BlouinV, ProvostN, et al.Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J Virol, 2002; 76:11605–11611.
9.
GernouxG, GuilbaudM, DubreilL, et al.Early interaction of adeno-associated virus serotype 8 vector with the host immune system following intramuscular delivery results in weak but detectable lymphocyte and dendritic cell transduction. Hum Gene Ther, 2015; 26:1–13.
10.
ToromanoffA, AdjaliO, LarcherT, et al.Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. Mol Ther J Am Soc Gene Ther, 2010; 18:151–160.
11.
BoisgeraultF, MingozziF. The skeletal muscle environment and its role in immunity and tolerance to AAV vector-mediated gene transfer. Curr Gene Ther, 2015; 15:381–394.
12.
BrantlyML, ChulayJD, WangL, et al.Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A, 2009; 106:16363–16368.
13.
FlotteTR, TrapnellBC, HumphriesM, et al.Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum Gene Ther, 2011; 22:1239–1247.
14.
JiangH, PierceGF, OzeloMC, et al.Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther, 2006; 14:452–455.
15.
RossCJD, TwiskJ, BakkerAC, et al.Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum Gene Ther, 2006; 17:487–499.
16.
WangZ, AllenJM, RiddellSR, et al.Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther, 2007; 18:18–26.
17.
YuasaK, YoshimuraM, UrasawaN, et al.Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther, 2007; 14:1249–1260.
18.
MendellJR, CampbellK, Rodino-KlapacL, et al.Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med, 2010; 363:1429–1437.
19.
Basner-TschakarjanE, MingozziF. Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions. Front Immunol, 2014; 5:350.
20.
MaysLE, WilsonJM. The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol Ther J Am Soc Gene Ther, 2011; 19:16–27.
21.
ArrudaVR, StedmanHH, HaurigotV, et al.Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood, 2010; 115:4678–4688.
22.
HaurigotV, MingozziF, BuchlisG, et al.Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. Mol Ther J Am Soc Gene Ther, 2010; 18:1318–1329.
23.
Le GuinerC, MontusM, ServaisL, et al.Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients. Mol Ther J Am Soc Gene Ther, 2014; 22:1923–1935.
24.
ToromanoffA, ChérelY, GuilbaudM, et al.Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther J Am Soc Gene Ther, 2008; 16:1291–1299.
25.
ChenuaudP, LarcherT, RabinowitzJE, et al.Optimal design of a single recombinant adeno-associated virus derived from serotypes 1 and 2 to achieve more tightly regulated transgene expression from nonhuman primate muscle. Mol Ther J Am Soc Gene Ther, 2004; 9:410–418.
26.
Latta-MahieuM, RollandM, CailletC, et al.Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Hum Gene Ther, 2002; 13:1611–1620.
27.
AurisicchioL, TomassiAD, MonicaNL, et al.Regulated and liver-specific tamarin alpha interferon gene delivery by a helper-dependent adenoviral vector. J Virol, 2005; 79:6772–6780.
28.
MoreauA, VandammeC, SegoviaM, et al.Generation and in vivo evaluation of IL10-treated dendritic cells in a nonhuman primate model of AAV-based gene transfer. Mol Ther Methods Clin Dev, 2014; 1:14028.
29.
AclandGM, AguirreGD, BennettJ, et al.Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther J Am Soc Gene Ther, 2005; 12:1072–1082.
30.
BankiewiczKS, ForsayethJ, EberlingJL, et al.Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther J Am Soc Gene Ther, 2006; 14:564–570.
31.
StiegerK, SchroederJ, ProvostN, et al.Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates. Mol Ther J Am Soc Gene Ther, 2009; 17:516–523.
32.
NathwaniAC, RosalesC, McIntoshJ, et al.Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther J Am Soc Gene Ther, 2011; 19:876–885.
33.
JaénML, VilàL, EliasI, et al.Long-term efficacy and safety of insulin and glucokinase gene therapy for diabetes: 8-year follow-up in dogs. Mol Ther Methods Clin Dev, 2017; 6:1–7.
34.
LeeYM, ConlonTJ, SpechtA, et al.Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia. J Inherit Metab Dis, 2018; 1–8.
35.
NiemeyerGP, HerzogRW, MountJ, et al.Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood, 2009; 113:797–806.
36.
SabatinoDE, LangeAM, AltynovaES, et al.Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther J Am Soc Gene Ther, 2011; 19:442–449.
37.
ElvermanM, GoddardMA, MackD, et al.Long-term effects of systemic gene therapy in a canine model of myotubular myopathy. Muscle Nerve, 2017; 56:943–953.
38.
Le GuinerC, ServaisL, MontusM, et al.Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun, 2017; 8:16105.
39.
BennettJ, WellmanJ, MarshallKA, et al.Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on Phase 1 trial. Lancet, 2016; 388:661–672.
40.
BuchlisG, PodsakoffGM, RaduA, et al.Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood, 2012; 119:3038–3041.
41.
Le MeurG, LebranchuP, BillaudF, et al.Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 Leber congenital amaurosis. Mol Ther, 2018; 26:256–268.
42.
MarksWJ, BaumannTL, BartusRT. Long-term safety of patients with Parkinson's disease receiving rAAV2-neurturin (CERE-120) gene transfer. Hum Gene Ther, 2015; 27:522–527.
43.
MuellerC, GernouxG, GruntmanAM, et al.5 Year expression and neutrophil defect repair after gene therapy in alpha-1 antitrypsin deficiency. Mol Ther, 2017; 25:1387–1394.
44.
ChenuaudP, LarcherT, RabinowitzJE, et al.Autoimmune anemia in macaques following erythropoietin gene therapy. Blood, 2004; 103:3303–3304.
45.
GaoG, LebherzC, WeinerDJ, et al.Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood, 2004; 103:3300–3302.
46.
HerzogRW, MountJD, ArrudaVR, et al.Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther, 2001; 4:192–200.
47.
ArrudaVR, SchuettrumpfJ, HerzogRW, et al.Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood, 2004; 103:85–92.
48.
ArrudaVR, StedmanHH, NicholsTC, et al.Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood, 2005; 105:3458–3464.
49.
AsokanA, JohnsonJS, LiC, et al.Bioluminescent virion shells: New tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther, 2008; 15:1618–1622.
50.
RipJ, NiermanMC, SiertsJA, et al.Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Hum Gene Ther, 2005; 16:1276–1286.
51.
ZhangK, ZhangY-Q, AiW-B, et al.Hes1, an important gene for activation of hepatic stellate cells, is regulated by Notch1 and TGF-β/BMP signaling. World J Gastroenterol, 2015; 21:878–887.
52.
LégerA, Le GuinerC, NickersonML, et al.Adeno-associated viral vector-mediated transgene expression is independent of DNA methylation in primate liver and skeletal muscle. PLoS One, 2011; 6:e20881.
53.
Penaud-BudlooM, Le GuinerC, NowrouziA, et al.Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol, 2008; 82:7875–7885.
54.
RiveraVM, GaoG, GrantRL, et al.Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood, 2005; 105:1424–1430.
55.
SuzukiM, BertinTK, RogersGL, et al.Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo. Mol Ther J Am Soc Gene Ther, 2013; 21:796–805.
56.
GernouxG, WilsonJM, MuellerC. Regulatory and exhausted T cell responses to AAV capsid. Hum Gene Ther, 2017; 28:338–349.
CramerML, ShaoG, Rodino-KlapacLR, et al.Induction of T-cell infiltration and programmed death ligand 2 expression by adeno-associated virus in rhesus macaque skeletal muscle and modulation by prednisone. Hum Gene Ther, 2017; 28:493–509.
59.
VelazquezVM, BowenDG, WalkerCM. Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector–mediated gene therapy. Blood, 2009; 113:538–545.
60.
FerreiraV, TwiskJ, KwikkersK, et al.Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPLS447X) in a Phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum Gene Ther, 2013; 25:180–188.
61.
MingozziF, HasbrouckNC, Basner-TschakarjanE, et al.Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood, 2007; 110:2334–2341.
62.
MingozziF, LiuY-L, DobrzynskiE, et al.Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest, 2003; 111:1347–1356.
63.
MountJD, HerzogRW, TillsonDM, et al.Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood, 2002; 99:2670–2676.
64.
DobrzynskiE, MingozziF, LiuY-L, et al.Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. Blood, 2004; 104:969–977.
65.
FanZ, KocisK, ValleyR, et al.Safety and feasibility of high-pressure transvenous limb perfusion with 0.9% saline in human muscular dystrophy. Mol Ther J Am Soc Gene Ther, 2012; 20:456–461.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
